Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Graves Ophthalmopathy | 10 | 2024 | 133 | 2.650 |
Why?
|
Orbital Diseases | 5 | 2018 | 178 | 2.020 |
Why?
|
Eyelid Neoplasms | 4 | 2019 | 89 | 1.980 |
Why?
|
Oculomotor Muscles | 6 | 2024 | 406 | 1.920 |
Why?
|
Conjunctival Neoplasms | 4 | 2017 | 77 | 1.690 |
Why?
|
Lacrimal Apparatus Diseases | 4 | 2024 | 72 | 1.650 |
Why?
|
Eyelid Diseases | 5 | 2024 | 157 | 1.590 |
Why?
|
Orbital Neoplasms | 6 | 2024 | 222 | 1.580 |
Why?
|
Scleral Buckling | 3 | 2022 | 95 | 1.580 |
Why?
|
Orbit | 7 | 2024 | 457 | 1.510 |
Why?
|
Eyelids | 9 | 2024 | 278 | 1.270 |
Why?
|
Polyhydroxyethyl Methacrylate | 3 | 2022 | 30 | 1.050 |
Why?
|
Eye Infections, Bacterial | 3 | 2018 | 242 | 1.010 |
Why?
|
Eye Neoplasms | 2 | 2017 | 307 | 0.950 |
Why?
|
Orbital Myositis | 2 | 2024 | 25 | 0.940 |
Why?
|
Sebaceous Gland Neoplasms | 2 | 2022 | 40 | 0.940 |
Why?
|
Retinal Detachment | 3 | 2022 | 429 | 0.840 |
Why?
|
Ophthalmologic Surgical Procedures | 5 | 2019 | 354 | 0.820 |
Why?
|
Sclera | 1 | 2024 | 190 | 0.820 |
Why?
|
Nasolacrimal Duct | 3 | 2024 | 79 | 0.810 |
Why?
|
Adenocarcinoma, Sebaceous | 1 | 2022 | 21 | 0.780 |
Why?
|
Panuveitis | 1 | 2022 | 33 | 0.780 |
Why?
|
Granular Cell Tumor | 1 | 2022 | 48 | 0.780 |
Why?
|
Myositis | 1 | 2024 | 269 | 0.730 |
Why?
|
Oxazolone | 1 | 2020 | 61 | 0.720 |
Why?
|
Melanocytes | 1 | 2024 | 509 | 0.700 |
Why?
|
Sweat Gland Neoplasms | 2 | 2022 | 116 | 0.680 |
Why?
|
Chalazion | 1 | 2019 | 10 | 0.670 |
Why?
|
Necrosis | 1 | 2024 | 1610 | 0.660 |
Why?
|
Impetigo | 1 | 2018 | 7 | 0.630 |
Why?
|
Eye Infections, Viral | 2 | 2016 | 60 | 0.620 |
Why?
|
Osteochondroma | 1 | 2017 | 44 | 0.580 |
Why?
|
Calcium Compounds | 1 | 2017 | 38 | 0.570 |
Why?
|
Abscess | 1 | 2021 | 606 | 0.560 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2017 | 4021 | 0.560 |
Why?
|
Eccrine Glands | 1 | 2017 | 52 | 0.560 |
Why?
|
Blepharitis | 1 | 2016 | 35 | 0.530 |
Why?
|
Dermatitis | 1 | 2018 | 202 | 0.530 |
Why?
|
Rhytidoplasty | 1 | 2017 | 71 | 0.530 |
Why?
|
Herpes Zoster Ophthalmicus | 1 | 2016 | 37 | 0.530 |
Why?
|
Choristoma | 1 | 2018 | 205 | 0.520 |
Why?
|
Myofibromatosis | 1 | 2016 | 27 | 0.520 |
Why?
|
Myofibroma | 1 | 2016 | 45 | 0.510 |
Why?
|
Blepharoplasty | 2 | 2014 | 61 | 0.510 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 178 | 0.510 |
Why?
|
Paranasal Sinus Diseases | 1 | 2016 | 121 | 0.500 |
Why?
|
Corneal Neovascularization | 1 | 2017 | 185 | 0.500 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2016 | 136 | 0.500 |
Why?
|
Conjunctival Diseases | 1 | 2016 | 110 | 0.480 |
Why?
|
Skin Ulcer | 1 | 2016 | 130 | 0.480 |
Why?
|
Conjunctiva | 1 | 2018 | 479 | 0.470 |
Why?
|
Keratitis | 1 | 2017 | 241 | 0.450 |
Why?
|
Exophthalmos | 3 | 2024 | 97 | 0.450 |
Why?
|
Carcinoma, Basal Cell | 1 | 2019 | 557 | 0.450 |
Why?
|
Communicable Diseases | 1 | 2022 | 871 | 0.440 |
Why?
|
Cysts | 2 | 2016 | 680 | 0.440 |
Why?
|
Veins | 1 | 2018 | 767 | 0.440 |
Why?
|
Rhabdomyosarcoma | 1 | 2016 | 358 | 0.430 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2016 | 237 | 0.430 |
Why?
|
Graves Disease | 1 | 2015 | 238 | 0.430 |
Why?
|
Eyebrows | 1 | 2013 | 37 | 0.410 |
Why?
|
Cicatrix | 1 | 2018 | 785 | 0.400 |
Why?
|
Pseudomonas Infections | 1 | 2016 | 621 | 0.390 |
Why?
|
Biopsy | 7 | 2018 | 6763 | 0.370 |
Why?
|
Iodine Radioisotopes | 1 | 2015 | 1031 | 0.370 |
Why?
|
Immunocompromised Host | 1 | 2016 | 858 | 0.370 |
Why?
|
Sonication | 1 | 2011 | 79 | 0.360 |
Why?
|
Dacryocystorhinostomy | 2 | 2024 | 78 | 0.360 |
Why?
|
Microbubbles | 1 | 2011 | 135 | 0.350 |
Why?
|
Hepatitis C, Chronic | 1 | 2017 | 1018 | 0.330 |
Why?
|
Retinal Neoplasms | 1 | 2011 | 148 | 0.320 |
Why?
|
Lacrimal Apparatus | 2 | 2024 | 223 | 0.310 |
Why?
|
Pseudomonas aeruginosa | 1 | 2016 | 1272 | 0.310 |
Why?
|
Retinoblastoma | 1 | 2011 | 319 | 0.310 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2017 | 2197 | 0.310 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2011 | 678 | 0.280 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 2821 | 0.280 |
Why?
|
Skin Neoplasms | 2 | 2019 | 5811 | 0.280 |
Why?
|
Humans | 56 | 2024 | 760740 | 0.270 |
Why?
|
Bone Neoplasms | 1 | 2017 | 2527 | 0.250 |
Why?
|
Melanoma | 1 | 2024 | 5696 | 0.250 |
Why?
|
Surgical Flaps | 3 | 2021 | 1670 | 0.240 |
Why?
|
Doxorubicin | 1 | 2011 | 2224 | 0.230 |
Why?
|
Limbus Corneae | 2 | 2016 | 143 | 0.230 |
Why?
|
Microphthalmos | 1 | 2024 | 58 | 0.230 |
Why?
|
Syringoma | 1 | 2022 | 8 | 0.210 |
Why?
|
Melanosis | 1 | 2024 | 93 | 0.210 |
Why?
|
Magnetic Resonance Imaging | 10 | 2024 | 36401 | 0.200 |
Why?
|
Tomography, X-Ray Computed | 9 | 2024 | 20556 | 0.200 |
Why?
|
Molecular Targeted Therapy | 1 | 2013 | 2812 | 0.200 |
Why?
|
Prosthesis Implantation | 2 | 2017 | 591 | 0.190 |
Why?
|
Entropion | 1 | 2020 | 9 | 0.190 |
Why?
|
Temporal Muscle | 1 | 2021 | 36 | 0.180 |
Why?
|
Ectropion | 1 | 2020 | 27 | 0.180 |
Why?
|
Female | 28 | 2024 | 392203 | 0.180 |
Why?
|
Middle Aged | 22 | 2024 | 220603 | 0.180 |
Why?
|
Nose | 1 | 2024 | 521 | 0.180 |
Why?
|
Muir-Torre Syndrome | 1 | 2020 | 12 | 0.170 |
Why?
|
Orbital Fractures | 1 | 2020 | 109 | 0.170 |
Why?
|
Retinitis | 1 | 2019 | 36 | 0.170 |
Why?
|
Administration, Oral | 2 | 2018 | 4010 | 0.160 |
Why?
|
Eye Enucleation | 2 | 2016 | 128 | 0.160 |
Why?
|
Male | 24 | 2024 | 360402 | 0.160 |
Why?
|
Glomerulonephritis, IGA | 1 | 2019 | 61 | 0.160 |
Why?
|
Adult | 18 | 2024 | 220995 | 0.160 |
Why?
|
Hydrolysis | 1 | 2019 | 661 | 0.160 |
Why?
|
Diagnosis, Differential | 3 | 2019 | 12966 | 0.150 |
Why?
|
Visual Acuity | 3 | 2017 | 2676 | 0.150 |
Why?
|
Clindamycin | 1 | 2018 | 139 | 0.150 |
Why?
|
Endoscopy | 3 | 2018 | 1851 | 0.140 |
Why?
|
Neoplasm, Residual | 1 | 2022 | 1008 | 0.140 |
Why?
|
Port-Wine Stain | 1 | 2016 | 33 | 0.130 |
Why?
|
Acyclovir | 1 | 2016 | 267 | 0.120 |
Why?
|
Optic Nerve Diseases | 1 | 2019 | 342 | 0.120 |
Why?
|
Herpesvirus 3, Human | 1 | 2016 | 159 | 0.120 |
Why?
|
Lymphangiogenesis | 1 | 2016 | 171 | 0.120 |
Why?
|
Neovascularization, Pathologic | 2 | 2016 | 2644 | 0.120 |
Why?
|
Nasal Mucosa | 1 | 2018 | 415 | 0.120 |
Why?
|
Valine | 1 | 2016 | 408 | 0.120 |
Why?
|
Bioartificial Organs | 1 | 2014 | 47 | 0.110 |
Why?
|
Injections | 1 | 2017 | 832 | 0.110 |
Why?
|
Adipose Tissue | 2 | 2024 | 3310 | 0.110 |
Why?
|
Eyelashes | 1 | 2014 | 19 | 0.110 |
Why?
|
Young Adult | 6 | 2024 | 59191 | 0.110 |
Why?
|
Eye Burns | 1 | 2014 | 65 | 0.110 |
Why?
|
Hemangioma, Cavernous | 1 | 2014 | 107 | 0.110 |
Why?
|
Panophthalmitis | 1 | 2013 | 6 | 0.110 |
Why?
|
Prostaglandins, Synthetic | 1 | 2013 | 24 | 0.110 |
Why?
|
Burns, Chemical | 1 | 2014 | 123 | 0.110 |
Why?
|
Eye Diseases | 1 | 2019 | 653 | 0.110 |
Why?
|
Viscosupplements | 1 | 2013 | 21 | 0.110 |
Why?
|
Orbital Cellulitis | 1 | 2013 | 33 | 0.110 |
Why?
|
Skin Abnormalities | 1 | 2013 | 59 | 0.100 |
Why?
|
Visual Fields | 1 | 2019 | 1062 | 0.100 |
Why?
|
Drug Combinations | 1 | 2018 | 2048 | 0.100 |
Why?
|
Aged, 80 and over | 6 | 2024 | 58919 | 0.100 |
Why?
|
Debridement | 1 | 2014 | 493 | 0.090 |
Why?
|
Inflammation | 2 | 2022 | 10759 | 0.090 |
Why?
|
Botulinum Toxins | 1 | 2013 | 189 | 0.090 |
Why?
|
Viral Load | 2 | 2017 | 3325 | 0.090 |
Why?
|
Prostheses and Implants | 1 | 2017 | 1269 | 0.090 |
Why?
|
Retrospective Studies | 11 | 2024 | 80583 | 0.090 |
Why?
|
Foreign Bodies | 1 | 2014 | 402 | 0.090 |
Why?
|
Molecular Biology | 1 | 2013 | 575 | 0.080 |
Why?
|
Vaccination | 1 | 2022 | 3370 | 0.080 |
Why?
|
Cell Membrane Permeability | 1 | 2011 | 574 | 0.080 |
Why?
|
Nephritis, Hereditary | 1 | 2009 | 78 | 0.080 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2011 | 944 | 0.080 |
Why?
|
Blindness | 1 | 2013 | 585 | 0.080 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1650 | 0.080 |
Why?
|
Adenoma | 1 | 2020 | 2159 | 0.080 |
Why?
|
Escherichia coli Infections | 1 | 2013 | 518 | 0.080 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3593 | 0.080 |
Why?
|
Glucocorticoids | 1 | 2018 | 2160 | 0.080 |
Why?
|
Herpesvirus 4, Human | 1 | 2014 | 1077 | 0.080 |
Why?
|
Eye Diseases, Hereditary | 1 | 2009 | 122 | 0.080 |
Why?
|
Corneal Diseases | 1 | 2014 | 542 | 0.080 |
Why?
|
Retinal Pigment Epithelium | 1 | 2011 | 303 | 0.080 |
Why?
|
Suture Techniques | 1 | 2013 | 768 | 0.070 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2014 | 614 | 0.070 |
Why?
|
Cell Count | 1 | 2011 | 1834 | 0.070 |
Why?
|
Drug Synergism | 1 | 2011 | 1756 | 0.070 |
Why?
|
Proteomics | 1 | 2020 | 3836 | 0.070 |
Why?
|
Aged | 11 | 2024 | 169092 | 0.070 |
Why?
|
Postoperative Complications | 2 | 2019 | 15609 | 0.070 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 4910 | 0.060 |
Why?
|
Flow Cytometry | 1 | 2016 | 5863 | 0.060 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1551 | 0.060 |
Why?
|
Tomography, Optical Coherence | 2 | 2016 | 2917 | 0.060 |
Why?
|
Pain | 1 | 2019 | 5062 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5838 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3607 | 0.060 |
Why?
|
Antiviral Agents | 1 | 2016 | 3037 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3801 | 0.050 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 6126 | 0.050 |
Why?
|
Glaucoma | 1 | 2013 | 1186 | 0.050 |
Why?
|
Retinal Diseases | 1 | 2009 | 704 | 0.050 |
Why?
|
Carcinoma | 1 | 2013 | 2328 | 0.050 |
Why?
|
Cell Survival | 1 | 2011 | 5780 | 0.050 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18220 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2014 | 4745 | 0.050 |
Why?
|
Asthma | 1 | 2019 | 6234 | 0.040 |
Why?
|
Sebaceous Glands | 1 | 2020 | 42 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 2222 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7403 | 0.040 |
Why?
|
MutS Homolog 2 Protein | 1 | 2020 | 197 | 0.040 |
Why?
|
Organ Size | 1 | 2024 | 2252 | 0.040 |
Why?
|
Ultrasonography | 1 | 2011 | 5965 | 0.040 |
Why?
|
Uncertainty | 1 | 2022 | 752 | 0.040 |
Why?
|
Disease Progression | 1 | 2015 | 13495 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2019 | 64572 | 0.040 |
Why?
|
Adolescent | 2 | 2024 | 88247 | 0.040 |
Why?
|
Hyperplasia | 1 | 2020 | 1150 | 0.030 |
Why?
|
ROC Curve | 1 | 2024 | 3575 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2016 | 26183 | 0.030 |
Why?
|
Child | 2 | 2022 | 80089 | 0.030 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2016 | 748 | 0.030 |
Why?
|
Glass | 1 | 2014 | 115 | 0.030 |
Why?
|
Cloprostenol | 1 | 2013 | 21 | 0.030 |
Why?
|
Prostaglandins F, Synthetic | 1 | 2013 | 32 | 0.030 |
Why?
|
Mice | 1 | 2020 | 81368 | 0.030 |
Why?
|
Child, Preschool | 1 | 2016 | 42193 | 0.030 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 664 | 0.030 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2019 | 1222 | 0.020 |
Why?
|
Lymphatic Vessels | 1 | 2016 | 356 | 0.020 |
Why?
|
Ophthalmoplegia | 1 | 2013 | 168 | 0.020 |
Why?
|
Blepharoptosis | 1 | 2013 | 144 | 0.020 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2014 | 647 | 0.020 |
Why?
|
Mycoses | 1 | 2014 | 386 | 0.020 |
Why?
|
Amides | 1 | 2013 | 449 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2014 | 1900 | 0.020 |
Why?
|
Subcutaneous Fat | 1 | 2013 | 393 | 0.020 |
Why?
|
Decompression, Surgical | 1 | 2014 | 606 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2014 | 1125 | 0.020 |
Why?
|
Drainage | 1 | 2014 | 1156 | 0.020 |
Why?
|
Animals | 1 | 2020 | 168202 | 0.020 |
Why?
|
Hyperpigmentation | 1 | 2009 | 116 | 0.020 |
Why?
|
Reoperation | 1 | 2018 | 4300 | 0.020 |
Why?
|
Fluorescence | 1 | 2009 | 756 | 0.020 |
Why?
|
Cornea | 1 | 2014 | 1332 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2013 | 20988 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2014 | 6074 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2014 | 3149 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11069 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18381 | 0.010 |
Why?
|
Prospective Studies | 2 | 2019 | 54364 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 12759 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12043 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2016 | 22153 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39062 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2013 | 26065 | 0.010 |
Why?
|
United States | 1 | 2019 | 72292 | 0.010 |
Why?
|
Concepts
(232)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(35)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_